Is this you?
Request access for Gastro Health Research with your @gastrohealth.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 7Lift (cardio sample) 0.31Recruit soph 0.43
Quality Scorecard (1–100)
Overall72Recruit62Ops74Sponsor79Ther74
Performance (observed)
Historical trials
364
Completed
196
Terminated/Withdrawn
55
Completion rate
78%
Active now
108
Phase 2
134
Phase 3
179
Realized enrollment
268,411
First study year
2003
Years active
23
Match confidence
high
Enrollment velocity (inf)
11,670
Therapeutic
Areas
Gastroenterology: Crohn's disease, ulcerative colitis, NASH, general GI
Specialties
Gastroenterology, hepatology, Crohn's disease, GI conditions, obesity
Breadth (conditions)
201
Languages
English
States
7 states: AL, FL, MD, MA, OH, VA, WA
Recruitment (web observed)
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Moderate; Research-focused web pages
Capability notes
Clinical research division with 350+ physicians across 150 locations. Named VP Clinical Research (Chris Fourment, MD, former GI Alliance research co-founder). Emphasis on advancing therapeutic development.
Relationships
Sponsors
Gilead Sciences; AbbVie; Hoffmann-La Roche; Pfizer; Shire; Eli Lilly and Company
CROs
ICON Clinical Research; PPD, Part of Thermo Fisher Scientific; Parexel; Premier Research; Teva Branded Pharmaceutical Products R&D LLC
Partnerships
University partnerships, national research program
Owner / parent
Private (350+ physicians, $71.7M annual revenue, founded 2006)
Capacity & people
Investigators
—
Coordinators
—
CEO
Alan Oliver (since May 2024)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Chris Fourment, MD (VP Clinical Research)
Tech & DCT
eSource
Yes
Builds tech
Unknown
Home visits
N
Tech stack
Unknown (not detailed on website)
Recruiting visible
Y
Notes
Large multi-state SMO with 350+ physicians and significant geographic footprint (7 states). Strong research leadership with VP Clinical Research hire from GI Alliance indicating growth in research operations. Physician recruitment/retention programs show operational sophistication. Good prospect for Intera as growth-focused SMO expanding research capabilities nationally. [Validated: 4 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 0.55Liftability 0.31Overall72
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.